Prices are updated after-hours

HARP

Harpoon Therapeutics, Inc.

HARP | $23.01 0.07% 6.6M

(0.0% 1d) (0.0% 1m) (3909.4% 1y) (0.0% 2d) (0.1% 3d) (0.0% 7d) (122.25% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 389,611,579
http://www.harpoontx.com
Sec Filling | Patents | 61 employees

(US) Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which develops a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTACs) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.

cancer immunotherapy glass t-cell treatment ceiling construction

add to watch list Paper trade email alert is off

Press-releases

Merck Completes Acquisition of Harpoon Therapeutics, Inc.
Published: 2024-03-11 (Crawled : 16:00) - biospace.com/
MRK | $127.0 0.1% 0.63% 5.7M

Health Technology

| 2.83% | O: 0.93% H: 0.0% C: -1.51%
merck acquisition

INVESTIGATION ALERT: Halper Sadeh LLC Investigates HARP, JNPR, TGAN, TAST
Published: 2024-02-06 (Crawled : 15:30) - prnewswire.com
TGAN | $4.83 -0.41% -0.41% 200K

Manufacturing

| -0.62% | O: -0.21% H: 0.62% C: 0.41%
QSR | $73.62 -0.98% 0.0% 960K

Consumer Services

| -4.91% | O: -0.34% H: 0.09% C: -1.06%
JNPR | $35.36 -1.45% 1.36% 4.7M

Technology Services

| -4.28% | O: 0.03% H: 0.32% C: 0.11%
HARP | $23.01 0.07% 6.6M

Health Technology

| 2.91% | O: -0.04% H: 0.22% C: 0.09%
TAST | $9.51 0.11% 260K

Consumer Services

| 1.06% | O: 0.21% H: 0.11% C: -0.21%

INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - BBAI, HARP, FGH, PGTI
Published: 2024-02-06 (Crawled : 03:00) - prnewswire.com
FGH | $1.24 -5.7% 0.0% 0

Information

| -16.22% | O: -1.35% H: 0.0% C: -5.14%
BBAI 4 | $1.69 -1.17% 0.0% 5.5M

n/a

| 6.96% | O: 1.27% H: 10.0% C: 8.75%
PGTI | $41.99 -0.0% 2.2M

Producer Manufacturing

| 1.87% | O: -0.02% H: 0.29% C: 0.22%
PGTI | $41.99 -0.0% 2.2M

Producer Manufacturing

| 1.87% | O: -0.02% H: 0.29% C: 0.22%
HARP | $23.01 0.07% 6.6M

Health Technology

| 2.91% | O: -0.04% H: 0.22% C: 0.09%

Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
Published: 2024-02-01 (Crawled : 23:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310

Health Technology

| -6.93% | O: -4.37% H: 0.0% C: 0.0%
MRK | $127.0 0.1% 0.63% 5.7M

Health Technology

| 5.15% | O: 2.38% H: 2.25% C: 2.21%
SNY | News | $46.61 -2.27% -2.21% 1.6M

Health Technology

| -7.24% | O: -5.26% H: 0.0% C: 0.0%
MRNA | News S | $108.85 0.89% 0.85% 3M

Health Technology

| 7.72% | O: -0.15% H: 0.1% C: -1.86%
HARP | $23.01 0.07% 6.6M

Health Technology

| 2.96% | O: 0.0% H: 0.0% C: 0.0%
merck financial results

Harpoon Therapeutics Strengthens Leadership Team
Published: 2023-12-26 (Crawled : 12:30) - globenewswire.com
HARP | $23.01 0.07% 6.6M

Health Technology

| 97.68% | O: 5.93% H: 3.0% C: -2.76%
therapeutics

Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium
Published: 2023-12-19 (Crawled : 12:30) - globenewswire.com
HARP | $23.01 0.07% 6.6M

Health Technology

| 134.35% | O: 10.6% H: 0.0% C: 0.0%
hpn328 rapid symposium presentation therapeutics

Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)
Published: 2023-12-12 (Crawled : 02:00) - globenewswire.com
HARP | $23.01 0.07% 6.6M

Health Technology

| 161.4% | O: 7.11% H: 3.61% C: -7.11%
hpn217 therapeutics

Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
Published: 2023-11-02 (Crawled : 13:00) - globenewswire.com
HARP | $23.01 0.07% 6.6M

Health Technology

| 355.25% | O: 0.0% H: 4.16% C: 2.18%
hpn217 presentation meeting therapeutics

Harpoon Therapeutics Announces Up to $150 Million Private Placement
Published: 2023-10-23 (Crawled : 11:00) - globenewswire.com
HARP | $23.01 0.07% 6.6M

Health Technology

| 283.81% | O: 18.03% H: 3.25% C: -25.32%
therapeutics

Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
Published: 2023-10-21 (Crawled : 16:20) - globenewswire.com
HARP | $23.01 0.07% 6.6M

Health Technology

| Email alert Add to watchlist
hpn328 congress cell trial therapeutics response

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0000950170-24-029449	4	2024-03-11	2024-03-11	Sell	D	299430	0
0000950170-24-029449	4	2024-03-11	2024-03-11	Sell	D	10000	0
0000950170-24-029449	4	2024-03-11	2024-03-11	Sell	D	1463386	0
0000950170-24-029447	4	2024-03-11	2024-03-11	Sell	D	2033	0
0000950170-24-029447	4	2024-03-11	2024-03-11	Sell	D	5000	0